Hiya, sorry but I don't know. No agreement details have been released and AT1 hadn't sold enough to disclose Ag numbers vs revenue in FY21 (eg: we know 50k Ab tests were sold but not how many Ag)
Speculating, yes, $1-$3 seems reasonable to me if the volume price will be $10-$15 (as Access Bio would retain the larger share as manufacturer, brand packaging etc and AT1 would have local sale, regulatory and shipping costs to cover).
I have asked the Q in the Coffee MicroCaps presentation (on currently) so will post if it gets answered shortly.
Media Update, page-1005
-
- There are more pages in this discussion • 841 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 497908 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 67200 | 3 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable